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primary and/or its metastases in patients with non-small-
cellular-lung-cancer (NSCLC) can lead to a favourable 
progression-free- (PFS) and overall-survival- rates (OS). An 
analysis made for patients treated between 2008 and 2012 at 
our institution already showed encouraging results. We 
extended this group of patients to those treated till 2015. 
 
Material and Methods: Between 2008 and 2015 a total of 58 
patients at our centre with an initial stage IV NSCLC with a 
maximum of 4 metastases at time of diagnosis received local 
radical treatment to all tumor sites. Method of treatment 
was indicated by the centre’s interdisciplinary tumor board 
review. This retrospective analysis acquired data using our 
comprehensive cancer centre’s patient-databases, that 
collected the patients’ data and by contacting the patients’ 
GP or their oncologists outside our institution.  
 
Results: Between 2012 and 2015 a total of 58 patients (43 
men (74%) and 15 women (26%)) where diagnosed with stage 
IV NSCLC, having less than 5 distant metastases. The median 
age at the time of diagnosis was 59 (range 48-86 years). The 
Karnofsky Performance Score (KPS) at a median of 90% (70-
100%). The staging was completed by, MRI, CT and/or PET/CT 
(47 cases; 81%) as well as by histopathological examination. A 
biopsy was available in all patients. 43 (74%) had an 
adenocarcinoma, while 15 patients (26%) had a squamous cell 
carcinoma. Mutation analyses of epidermal growth factor 
receptor (EGFR) was determined in 26 patients, of which 4 
(15%) showed a mutation. The patients underwent either 
surgery (74%) or radiotherapy (100%) of the primary or its 
metastases or a combination of both. Main target volumes 
were the primary, the mediastinum, brain metastases or 
bone metastases. Total cumulative doses at the site of the 
primary had a median of 60 Gy (30-68Gy). 45 patients (78%) 
were systemically treated. Out of these, 16 patients (28%) 
received a combined radio-chemotherapy with cisplatin, 
whereas 29 individuals obtained chemotherapy alone (50%) at 
some point in their history. Radiotherapy was generally well 
tolerated. One patient had grade three pneumonitis, 
requiring hospitalisation. Grade one toxicity occurred in four 
cases. During cytotoxic treatment one patient suffered grade 
three nausea. Mild to moderate cytopenia occurred in four 
patients. Median follow-up-time (FU) was 12.3 months, 
median PFS 6 months (95%, CI: 3.378-6.622%), while mean OS 
was 20 months, median OS was 15 months (95%, CI: 7.068-
16.932%). 
 
Conclusion: In line with literature, our analysis showed that 
radical treatment of patients with oligometastatic NSCLC 
may lead to an improvement of PFS and of the OS. 
Appropriate groups of patients with high KPS might benefit 
the most. Treatment modalities are generally well tolerated. 
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Purpose or Objective: Only few experiences had investigated 
the use of SABR for locally advanced NSCL centrally located. 
The RTOG 0236 Trial warns about the risks of SBRT in NSCLS 
located within 2 cm of the bronchial tree, the edophagus, 
heart and pericardium. The aim of this study is to evaluate 
the use of hypofracionated ablative radiotherapy in this 
setting of disease in terms of local control, toxicities and 
overall survival (OS). 
 
Material and Methods: Between Jun 2011 and March 2015 36 
patients (pts) were treated with Hypofrationated Image 
guided-Volumetric Modulated Arc Therapy (IGRT-VMAT) for 
centrally located NSCLC stage III-IV or centrally recurrent 
NSCLC biopsy-proven. Target was contoured using volumetric 
mdc enhanced CT and PET/CT scan and OAR according RTOG 
0236 Trial criteria. Dose Constraints used were: Single lung 
V10<20%, Dmax bronchus 38 Gy, Dmax esophagus 35 Gy, 
Spinal Cord 22.5 Gy, Heart and pericardium 38 Gy. The dose 
was prescribed to 80% isodose. The VMAT treatment was 
delivered by 6MV beam modulator Linac with 4 mm MLC and 
in breath hold using ABC device. Patient set-up and isocenter 
position was controlled before each fraction by CBCT. Target 
volume ranged from 21 to 150 cm3 (median 49.5). Median 
delivered dose was 40 Gy/5fx (median BED 10 of 100 Gy). 
Toxicities were assessed by CTCAE 4.0 criteria and the 
response was evaluated 2 months after the end of SBRT and 
every 4 month successively by CT and PET/CT. 
 
Results: Median follow-up was 18 months (range 3 – 45). 25 
pts are still alive (69.5%) and 8 of them have NED. 19/36 
(52.8%) of treated lesions show complete respons and 10 
(27.7%) partial response. Local control was 89% at 12 months 
and 67% at 18 months. OS was 84% and 73% at 12 and 18 
months respectively. Acute toxicity worse than G2 was 
observed only in 1 pt. Late toxicity G3 was observed in 3 pts 
(esophageal stenosis in 1 case and bronco-esophageal fistula 
in 2 pts). Both fistulas occour in the same site of local 
recurrence 
 
Conclusion: In our experience hypofractionated treatment 
with ablative dose for NSCLC locate in “no fly zone” is safe if 
dose constraints for OAR are respected. The two major late 
toxicities observed occurred in the same site of local 
recurrence. The treatments with BED 10 values of 100 Gy or 
more are effective leading to LC rate of 89% and 67% at 12 
and 18 month respectlively. Although OS is not the primary 
endpoint of this study, beacuse include also metastatic and 
recurrent disease, nevertheless shows interesting values (84% 
at 12 months and 73% at 18 months) 
 
EP-1254  
Updated outcomes for patients treated with SABR for lung 
cancer at the Leeds Cancer Centre 
P. Murray
1St James' Institute of Oncology, Clinical Oncology, Leeds, 
United Kingdom 
1, K. Spencer1, P. Dickinson1, M. Snee1, P. Jain1, K. 
Clarke1, K. Franks1 
 
Purpose or Objective: To report ongoing longer-term 
outcomes of a large cohort of patients undergoing SABR for 
primary stage I lung cancer at the Leeds Cancer Centre. 
 
Material and Methods: Patients were prospectively selected 
and received SABR for medically inoperable peripheral early 
stage lung cancer between May 2009 and January 2014. 
Electronic records were reviewed for baseline 
characteristics, treatment details and recorded toxicity and 
outcomes. 
 
Results: 572 patients underwent SABR treatment, with 43 of 
these patients receiving 2 or more treatments, either 
concurrently or sequentially. Median follow-up 24 months 
(IQR 14-35 months, range 0-76 months). Kaplan-Meier (KM) 
estimated Median Overall Survival (OS) was 33 Months (S.E. 
2.43 Months), and estimated 5-year OS 29.5% (S.E. 6%). 128 
patients had clinical and radiologically reported recurrence. 
26 patients (4.5%) developed local recurrence, 25 (4.3%) 
developed nodal recurrence, with 77 patients developing 
distant disease (13.5%). One, two and three-year K-M local 
control rates were 98.7% (S.E. 0.5%), 95.8% (S.E. 1.0%), and 
92.3% (S.E. 1.6%) respectively. 94(21.2%) patients had a 
radiological report of pneumonitis (G1), 31(6.6%) patients 
had a clinical diagnosis of pneumonitis recorded (G2) and 2 
(0.4%) patients had an episode of Grade 3 pneumonitis. 37 
patients had a radiologically reported rib fracture, 14 
symptomatic (2.9%) and 23 (4.8%) were asymptomatic (G1-2). 
There was no other reported ≥3 toxicity. Cox regression 
analysis showed that factors significantly associated with 
survival were poorer performance status (P=0.002) and 
increasing tumour size (p=0.008). Other factors such as 
histology, treatment related fibrosis, tumour lobar location, 
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Conclusion: SABR for primary lung cancer performed at the 
Leeds Cancer Centre continues to show excellent local 
control rates, with low toxicity and has comparable overall 5-
year survival rates to other published series. Poorer 
performance status and larger tumour size were associated 
with a negative effect on overall survival. 
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Purpose or Objective: To investigate the prognostic value of 
[(18)F] fluorodeoxyglucose positron emission tomography 
(FDG-PET) uptake before stereotactic ablative radiotherapy 
(SABR) for stage I non-small-cell lung cancer (NSCLC). 
 
Material and Methods: From August 2009 to December 2014, 
80 medically inoperable patients with proven Stage I NSCLC 
or FDG-PET-positive primary lung tumors were analyzed 
retrospectively. SABR consisted of 48-50 Gy delivered in 4 to 
5 fractions, respectively by two or one fraction per week. 
Maximum standardized uptake value (SUV (max)) of the 
treated lesion was assessed before SABR. Patients were 
subsequently followed at regular intervals using computed 
tomography (CT) and FDG-PET scans. Association between 
post-SABR SUV (max, at minimum of 12 weeks after 
treatment) and local control (LC), overall survival (OS) was 
examined. 
 
Results: Median follow-up time was 20 months (range, 9-55 
months). Median lesion size was 20 mm (range, 8-50 mm). 
Due to statistical evaluations around the median range of SUV 
(max), a pre SABR SUV (max) 5.0 was selected as a cut-off to 
analyze LC and OS. The 2-year LC was 61.2% versus 78.7% for 
higher or equal than 5.0 versus lower than 5.0 SUV (max), 
yielding an adjusted sub-hazard ratio (SHR) for high pre SABR 
SUV (max) of 5.3 (95% confidence interval [CI], 1.3-25.5; p = 
0.057). Two-year OS was 80.6% versus 76.6% respectively 
(hazard ratio [HR], 1.4; 95%; p = 0.46). No differences were 





Conclusion: FDG uptake (SUV (max) ≥5.0) before SABR 
signifies reduces risk of local failure. These results from 
single institution might stimulate a large accrual from 
multicenter prospective analysis, due to controversial results 
already published. 
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Purpose or Objective: To report our initial experience in 
stereotactic body radiation therapy (SBRT) delivered using 
RapidArc (RA) technique with or without flattening filter 
beam in terms of toxicity and clinical outcomes. 
 
Material and Methods: From September 2013 to September 
2015, 16 consecutive patients with 27 metastatic hepatic 
lesions were treated with SBRT in a TrueBeam unit using RA 
technique. 6 lesions received a Volumetric Modulated Arc 
Therapy (VMAT) treatment using 6Mv RA with flattening filter 
and 21 were treated without flattening filter (flattening filter 
free beam- FFF) with an energy of 10Mv. GTV was defined 
using multi-phase CT scans, PET/CT and/or MRI. The lesions 
were marked with a radiopaque coil to localize them in the 
verification CBCT (ConeBeamCT) that was performed daily. 
ITV (internal target volume) was calculated in gated modality 
with internal coil tracking by 2D imaging. Prescribed doses 
ranged from 30-60Gy in 3-5 fractions to ITV. The dose was 
downscaled in cases of not full achievement of dose 
constraints. 99.5% of the target volume was covered by 100% 
of the prescription dose. Initially, we followed the 
constraints proposed by Timmerman: Three fractions 
constraints for organs at risk were: 700cc of liver free from 
the 17.1Gy isodose, Dmax< 24Gy for stomach and duodenum, 
D5cc< 15Gy for duodenum, Dmax< 30Gy for heart, D1.2cc< 
11Gy and D0.25Gy< 18Gy for spinal cord. Five fractions 
constraints for organs at risk were: 700cc of liver free from 
the 21Gy isodose, Dmax< 32Gy for stomach and duodenum, 
D5cc< 18Gy for duodenum, Dmax< 38Gy for heart, D1.2cc< 
13.5Gy and D0.25Gy< 22.5Gy for spinal cord. Nowadays we 
are following the constraints proposed by the Spanish Society 
of Radiation Oncology: Liver: 700cc of liver free from the 
15Gy isodose, V21<30%, V15<20Gy, Mean dose: <15Gy for 
three fractions and <20Gy for five fractions; D5cc<15Gy for 
duodenum; V30<1cc and V21<5cc for heart; Dmax<18Gy for 
spinal cord. 
 
Results: Mean age of the patients was 59 years and the mean 
following time since the end of SBRT was 9.14 months. ITV 
mean volume was 41.78cc. The most frequent side effect was 
acute asthenia and we identified two cases of asymptomatic 
increase in liver enzymes. No patient experienced acute 
toxicity greater than Grade 2. In relation to the local 
response, we used RECIST and/or PERCIST criteria to 
reevaluate the lesions. We found 15 complete and 1 partial 
responses, 1 progression, 5 stable lesions and 2 pseudo 
progressions. 2 patients (4 lesions) were lost in the long-term 
clinical follow up. No differences between both treatment 
modalities (with or without FF) were found in terms of local 
control or side effects (either acute or chronic). 
 
Conclusion: SBRT for liver targets delivered by means of 
RapidArc resulted to be a feasible technique, with few side 
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